Hyperprolactinaemia and antipsychotic therapy in schizophrenia

References

• Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35(Suppl):S67–73
   Google Scholar
• Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365–73
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381–91
   PubMedGoogle Scholar
• Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14:163–73
   PubMedGoogle Scholar
• Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(Suppl 1):53–67
   PubMed Web of Science ®Google Scholar
• Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab 1996;81:586–90
   PubMed Web of Science ®Google Scholar
• Diver MJ, Ewins DL, Worth RC, Bowles S, Ahlquist JA, Fahie-Wilson MN. An unusual form of big, big (macro) prolactin in a pregnant patient. Clin Chem 2001;47:346–8
   Google Scholar
• Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 1994;35:151–63
   PubMed Web of Science ®Google Scholar
• Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354–69
   PubMed Web of Science ®Google Scholar
• Nielsen JH, Svensson C, Galsgaard ED, Moldrup A, Billestrup N. Beta cell proliferation and growth factors. J Mol Med 1999;77:62–6
   PubMed Web of Science ®Google Scholar
• Shingo T, Gregg C, Enwere E, et al. Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin. Science 2003;299:117–20
   PubMed Web of Science ®Google Scholar
• Exton MS, Kruger TH, Koch M, Paulson E, Knapp W, Hartmann U, Schedlowski M. Coitus-induced orgasm stimulates prolactin secretion in healthy subjects. Psychoneuroendocrinology 2001;26:287–94
   PubMed Web of Science ®Google Scholar
• Kruger TH, Haake P, Hartmann U, Schedlowski M, Exton MS. Orgasm-induced prolactin secretion: feedback control of sexual drive? Neurosci Behav Rev 2002;26:31–44
   Google Scholar
• Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999;44:1085–90
   PubMed Web of Science ®Google Scholar
• Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44:1075–84
   PubMed Web of Science ®Google Scholar
• Tuck SP, Francis RM. Osteoporosis. Postgrad Med J 2002;78:526–32
   PubMed Web of Science ®Google Scholar
• Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511–14
   PubMed Web of Science ®Google Scholar
• Hui SL, Slemenda CW, Johnston CC, Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804–9
   PubMed Web of Science ®Google Scholar
• Cann CE, Martin MC, Genant HK, Jaffe RB. Decreased spinal mineral content in amenorrheic women. JAMA 1984;251:626–9
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. Endocrinol Metab Clin North Am 1997;26:295–311
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629–34
   PubMed Web of Science ®Google Scholar
• Cohen AD, Cohen Y, Maislos M, Buskila D. Prolactin serum level in patients with breast cancer. Israel Med Assoc J 2000;2:287–9
   PubMed Web of Science ®Google Scholar
• Mandala M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, Curigliano G, Barni S. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. Oncology 2002;63:370–7
   PubMed Web of Science ®Google Scholar
• Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003;5:239–47
   PubMed Web of Science ®Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(Suppl)10:5–14
   Google Scholar
• Nordstrom AL, Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998;18:305–10
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33:279–86
   PubMed Web of Science ®Google Scholar
• Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978;35:108–16
   PubMed Web of Science ®Google Scholar
• Crawford AM, Beasley CM, Jr., Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41–54
   Google Scholar
• David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085–96
   PubMed Web of Science ®Google Scholar
• Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 1972;130:349–54
   PubMed Web of Science ®Google Scholar
• Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992;11:851–6
   PubMedGoogle Scholar
• Brown WA, Laughren TP. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 1981;5:317–22
   PubMed Web of Science ®Google Scholar
• Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 1985;40:95–8
   PubMedGoogle Scholar
• Beasley CM, Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111–23
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549–57
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233–46
   Google Scholar
• Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001;21:717–30
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49\(Suppl 1):5S–13S
   Google Scholar
• Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550–5
   PubMed Web of Science ®Google Scholar
• Schulz E, Fleischhaker C, Remschmidt HE. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol 1996;6:119–31
   PubMed Web of Science ®Google Scholar
• Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9:239–45
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57–61
   PubMed Web of Science ®Google Scholar
• Schlosser R, Grunder G, Anghelescu I, Hillert A, Ewald-Grunder S, Hiemke C, Benkert O. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46:33–40
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Unterweger B, Barnas C, Stuppack C, Hinterhuber H. Results of an open phase II study with zotepine – a new neuroleptic compound. Pharmacopsychiatry 1987;20:64–6
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Psychiatry Res 1999;89:115–22
   PubMed Web of Science ®Google Scholar
• Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14:209–18
   PubMed Web of Science ®Google Scholar
• Brambilla F, Guastalla A, Guerrini A, Rovere C, Legnani G, Sarno M, Riggi F. Prolactin secretion in chronic schizophrenia. Acta Psychiatr Scand 1976;54:275–86
   PubMed Web of Science ®Google Scholar
• Luchins DJ, Robertson AG, Meltzer HY. Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia. Psychiatry Res 1984;12:149–53
   PubMed Web of Science ®Google Scholar
• Otani K, Kondo T, Kaneko S, Ishida M, Fukushima Y. Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol 1994;9:287–9
   PubMed Web of Science ®Google Scholar
• Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(Suppl 2):109–23
   PubMed Web of Science ®Google Scholar
• Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143–64
   PubMedGoogle Scholar
• Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137–41
   PubMed Web of Science ®Google Scholar
• Beumont PJ, Gelder MG, Friesen GH, Harris GW, MacKinnon PC, Mandelbrote BM, Wiles DH. The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry 1974;124:413–19
   PubMed Web of Science ®Google Scholar
• Baastrup PCT, I., Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980;6:56–9
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485–91
   PubMed Web of Science ®Google Scholar
• Zhang-Wong JH, Seeman MV. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch Women Ment Health 2002;5:93–8
   PubMedGoogle Scholar
• Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761–6
   PubMed Web of Science ®Google Scholar
• Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002;112:817–28
   PubMed Web of Science ®Google Scholar
• Hummer M, Malik P, Gasser R, Kemmler G, Oehl M, Hofer A, Moncayo F, Fleischhacker WW. Osteoporosis in patients suffering from schizophrenia. Schizophr Res 2003;60:357
   Web of Science ®Google Scholar
• Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2003;59:17–8
   PubMed Web of Science ®Google Scholar
• Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28(Suppl 2):97–108
   PubMed Web of Science ®Google Scholar
• Izumotani K, Hagiwara S, Izumotani T, Miki T, Morii H, Nishizawa Y. Risk factors for osteoporosis in men. J Bone Miner Metab 2003;21:86–90
   PubMed Web of Science ®Google Scholar
• Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health 2002;26:292–8
   PubMedGoogle Scholar
• Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20:247–52
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Häfner H, Maurer K, Stummbaum M, Schmidt R. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophr Res 1992;6:114–5
   Web of Science ®Google Scholar
• Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt C, Resch F. Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Women Ment Health 2002;5:119–26
   PubMedGoogle Scholar
• Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. Br Med J 2002;324:250–2
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H. Estrogen – a potential treatment for schizophrenia. Schizophr Res 2001;48:137–44
   PubMed Web of Science ®Google Scholar
• Goode DJ, Corbett WT, Schey HM, Suh SH, Woodie B, Morris DL, Morrisey L. Breast cancer in hospitalized psychiatric patients. Am J Psychiatry 1981;138:804–6
   PubMed Web of Science ®Google Scholar
• Mortensen PB. Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients. Acta Psychiatr Scand 1987;75:585–90
   PubMed Web of Science ®Google Scholar
• Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002;59:1147–54
   PubMed Web of Science ®Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57 Suppl 11:40–5; discussion 6–52
   Google Scholar
• Peverill RE. Hormone therapy and venous thromboembolism. Baillières Best Pract Res Clin Endocrinol Metab 2003;17:149–64
   PubMed Web of Science ®Google Scholar
• Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435–40
   PubMed Web of Science ®Google Scholar